Report on New Patented Drugs - MultiHance
Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB's Price Guidelines for all new active substances introduced after January 1, 2002.
Brand Name: MultiHance
Generic Name: (gadobenate dimeglumine)
DIN: 02248302 529 mg/ml
Patentee: Bracco Diagnostic Canada
Indication - as per product monograph:
MultiHance is indicated for intravenous use in adults and children 2 years of age and older as an adjunct to magnetic resonance imaging (MRI) of the Central Nervous System (brain, spine, and surrounding structures).
Notice of Compliance: March 31, 2004
Date of First Sale: October 25, 2004
ATC Class: V08CA08
Various, Contrast Media, Magnetic Resonance Imaging Contrast Media, Paramagnetic Contrast Media
Application of the Guidelines:
The introductory price of MultiHance was found to be within the Guidelines because the cost of therapy did not exceed the cost of therapy of existing drugs in the therapeutic class comparison (TCC) and the price did not exceed the prices in other comparator countries where MultiHance was sold.
MultiHance is a new active substance and the PMPRB's Human Drug Advisory Panel (HDAP) recommended that MultiHance be reviewed as a category 3 new medicine (provides moderate, little or no therapeutic advantage over comparable medicines).
The HDAP recommended Omniscan (gadodiamide), Magnevist (gadopentate dimeglumine), Gadovist (gadobutrol), ProHance (gadoteridol) and Optimark (gadoversetamide) as the most appropriate comparators for MultiHance. These products share the same fourth level ATC class and are all used as adjunct for magnetic resonance imaging.
The PMPRB's Guidelines provide that the dosage recommended for comparison purposes will normally not be higher than the maximum of the usual recommended dosage. The recommended dosage regimens for MultiHance and the comparators are based on their respective product monographs and supported by clinical literature.
Under the Guidelines, the introductory price of a new category 3 drug product will be presumed to be excessive if it exceeds the price of all of the comparable drug products in the TCC test, or if it exceeds the prices of the same medicine in the seven countries listed in the Patented Medicines Regulations. The price of MultiHance was within the Guidelines as the daily cost of therapy did not exceed the cost of therapy with the comparator medicines.
||Cost per Treatment
|MultiHance (gadobenate dimeglumine)
|Magnevist (gadopentate dimeglumine)
1 Company price list dated July 29, 2005
2 Publicly available price as per the Patented Medicines Regulations
3 PPS Pharma
In 2004, MultiHance was being sold in France, Germany, Italy, Sweden, Switzerland and the United Kingdom. In compliance with the Guidelines, the price in Canada did not exceed the prices in those countries; the price of MultiHance in Canada was the lowest of those countries, below the median international price.
Where comparators and dosage regimens are referred to in the Summary Reports, they have been selected by the PMPRB Staff and the HDAP for the purpose of carrying out the PMPRB´s regulatory mandate, which is to review the prices of patented medicines sold in Canada to ensure that such prices are not excessive. The publication of these reports is also part of the PMPRB´s commitment to make its price review process more transparent.
The information contained in the PMPRB's Summary Reports should not be relied upon for any purpose other than its stated purpose and is not to be interpreted as an endorsement, recommendation or approval of any drug nor is it intended to be relied upon as a substitute for seeking appropriate advice from a qualified health care practitioner.
1. Carvlin MJ, et al, (1992) Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent. Invest Radiol 27, s16-s21.
2. Essig M, et al (2002) [Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers]. Radiology, 42(11):909-915.
3. Essig M, (2003) Clinical experience with MultiHance in CNS imaging. Eur Radiol 13:N3-N10.
4. Goldstein, HA, et al (1990) Safety assessment of gadopentetate dimeglumine in US clinical trials. Radio 174, 17-23.
5. Goyen, M, et al, (2001) 0.5 M Gd Chelate (Magnevist) versus 1.0 M Gd Chelate (Gadovist): Dose-Independent Effect on Image Quality of Pelvic Three-Dimensional MR-Angiography. J Mag Resonance Imaging 14:602-607.
6. Grossman, RI, et al, (2000) Magnetic Resonance Imagingin patients with central nervous system pathology: a comparison of OptiMark and Magnevist. Invest Radiol 35:412-419.
7. De Haen C, et al (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 Suppl 1:S161-8.
8. Kirchen, MA, et al, (2003) Contrast Agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 14:426-435.
9. Niendorf, HP, et al, (1991), Tolerance data of Gd-DTPA: a review. Eur J Radiol 13, 15-20.
10. Product Monographs, Compendium of Pharmaceutical Specialties.
11. Rocklage SM, et al (1992) Contrast agents in magnetic resonance imaging. Chapter 14, Magnetic Resonance Imaging, 2nd Ed, Stark and Bradley, Mosby Yearbook, 1992.
12. Runge VM, et al (1990) Gd-HP-DO3A in clinical MR imaging of the brain. Radiol 177, 393-400.
13. Runge VM, et al (1991) Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiol 181:701-709.
14. Runge VM, et al (2001) A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 36(2):65-71.
15. Runge VM, et al (1991) Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37(5):269-80.
16. Tombach, B, et al, (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) inpatients with chronic renal failure: results of a randomized study. Radiology 218:651-657.
17. Tweedle MF, et al (1988); Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 23(suppl 1), s236-s239.
18. Tweedle MF, et al (1991) Reaction of gadolinium chelates with endogenously available ions. Mag Res Imag 9, 409-415.
19. Tweedle MF, et al (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27, s2-s6.
20. Wendland MF, et al (1997) Alterations in T1 of normal and referfused infracted myocardium after Gd-BOPTA versus Gd-DTPA on inversion recovery EPI. Magn Reson Med 37(3):448-56.